Funding for this research was provided by:
Fondation de France (2014 000447967)
National project CHOPIN (CHolesterol Personalized Innovation), granted by the Agence Nationale de la Recherche (ANR-16-RHUS-0007)
Text and Data Mining valid from 2018-11-06
Received: 20 May 2018
Accepted: 15 October 2018
First Online: 6 November 2018
Ethics approval and consent to participate
: The HYPOPSY study was based on a retrospective medical and biological record review (ExternalRef removed identifier: NCT02889614), and was approved by the local Research Ethics Committee on the 03/11/2015 (Groupe Nantais d’Ethique dans le Domaine de la Santé). The database has been declared to the CNIL (Commission Nationale de l'Informatique et des Libertés) – registration number: 2015-019. According to French law, the retrospective and non-interventional design of this study made the consent of the patients unnecessary.
: Not applicable
: BC has received research funding from Sanofi, Regeneron and Pfizer and honoraria from Amgen, MSD (Merck & Co,), Regeneron, Sanofi outside of this submitted work. The other authors have nothing to disclose.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.